Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
Date:3/22/2011

avenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org or the HAEi (International Patient Organization for C1 Inhibitor Deficiencies) at www.haei.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®,
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
2. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
3. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
6. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
9. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
10. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
11. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
(Date:9/16/2014)... RICHMOND, Va. , Sept. 16, 2014 /PRNewswire-USNewswire/ ... (NAMCP) Medical Directors Institute has simultaneously released the ... the NAMCP Medical Diagnostics Dossier Template © , ... dossier template formats for either medical devices or ... unique aspects of each of these technology types ...
(Date:9/16/2014)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... therapies for solid tumor cancers, announced today that its ... as a "Promising Innovative Medicine" (PIM) under the new ... UK in April 2014.  A PIM is the first ... under the EAMS.  The PIM designation ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5
... Sept. 20, 2011 TheraVasc ( www.theravasc.com ) announced the ... drug, TV1001, to diabetic patients. The trial included 12 diabetic ... oral formulations of TV1001, an enteric coated and a non-enteric ... drug.  Based on prior studies conducted in animals, the circulating ...
... American Medical Systems (AMS), a leading provider of world-class ... today announced the launch of a new consumer friendly website ... partners learn how penile prosthetic implants can restore sexual function ... the popularity of ED medications, these drugs fail to resolve ...
Cached Medicine Technology:TheraVasc Releases Phase I Trial Data Demonstrating Safety of Drug in Diabetic Patients 2New Website Provides Comprehensive Resource to Anyone With Erectile Dysfunction 2New Website Provides Comprehensive Resource to Anyone With Erectile Dysfunction 3
(Date:9/16/2014)... Francisco, September 15, 2014A prospective study that compared ... patients with bone metastases demonstrates that single fraction ... multiple fraction radiation therapy (MFRT) when pain, function ... research presented today at the American Society for ... study indicates that improvements in patients, pain, function ...
(Date:9/16/2014)... 16, 2014 Fresh shiitake mushrooms ... and potassium. They are second-most consumed mushroom worldwide, ... their healing and health properties. , In addition ... can stimulate and strengthen the immune system and ... polycharrides, including beta glucans . These medicinal ...
(Date:9/16/2014)... 16, 2014 Synergy Research Group has ... gives the best detail and analysis of the state ... a variety of sources, including Ministry of Health in ... will give readers actionable intelligence on clinical trials in ... relied on by the local and international life science ...
(Date:9/16/2014)... Wholelifeinsurancecompanies.org has released a new blog post ... bad heart condition. , Clients who have a bad ... they compare quotes. Most agencies will insure applicants who ... actual and past medical condition. , If someone ... in the past, his or her chances of finding ...
(Date:9/16/2014)... had children (parous women) appear to have an ... the subtype that carries a higher mortality rate ... ancestry. A similar relationship was found for ... and increased risk of estrogen receptor-negative and triple-negative ... who had never breastfed. These findings, published in ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3Health News:Synergy Research Group Debuts Ukraine Orange Paper 2Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Lactation linked to reduced estrogen receptor-negative, triple-negative breast cancer risk 2
... The Food and Drug Administration (FDA) has awarded ... three-year, $1 million Orphan Products Development grant to ... the skin or internal organs., The unique, interdisciplinary, ... Beth Drolet, M.D., professor of dermatology and pediatrics, ...
... Governors Gene Therapeutics Research Institute at Cedars-Sinai Medical Center ... possible to sustain therapeutic gene expression in the central ... the presence of an anti-viral immune response mechanism that ... demonstrated in an animal model that the delivery system ...
... to be a multi-stage, multi-mechanism process by animal and ... Helicobacter pylori (H pylori) in the formation of gastric ... on November 7 in the World Journal of Gastroenterology ... H pylori on gastric cancer. , Gap junctions ...
... researchers say , THURSDAY, Oct. 25 (HealthDay News) -- ... can lessen cardiac injuries after heart attack and boost patient ... study in this week,s issue of The Lancet , ... muscle (infarct) and lessened what,s known as "reperfusion injuries," caused ...
... AMICAS, Inc (Nasdaq: AMCS ),announces the following Webcast: ... Webcast, When: November 1, 2007 @ 8:30 AM ET, ... the Internet -- Simply log on to the web at the ... Lisa Gould of AMICAS, Inc, 617-779-7892. If you are ...
... can search, sort, and compare more than 500 health ... plans on quality ... World Report and the,National Committee for Quality Assurance (NCQA) today ... ranking of U.S. health,maintenance organizations and point-of-service plans. Coinciding with ...
Cached Medicine News:Health News:Medical College of Wisconsin receives FDA grant 2Health News:Medical College of Wisconsin receives FDA grant 3Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: